Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. - Wikidata - awgldk - TriplyDB

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

http://www.wikidata.org/entity/Q40566975

about

Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets New antibody approaches to lymphoma therapy Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review T-cell lymphomas, a challenging disease: types, treatments, and future.Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.Immunopathogenesis and therapy of cutaneous T cell lymphoma.Mycosis fungoides: case report and literature review.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Cancer immunotherapy in clinical practice -- the past, present, and future.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.Treatment of mycosis fungoides: overview.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Management of the primary cutaneous lymphomas.Cutaneous T-cell lymphoma: a paradigm for biological therapies.Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.Therapeutic antibodies against cancer.Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.Emerging drugs in cutaneous T-cell lymphomas.Novel therapeutic agents for cutaneous T-Cell lymphoma.Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.Immunotherapy of cancer in 2012.Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy Standard and experimental therapy in cutaneous T-cell lymphomas.Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team Advances in the treatment for haematological malignancies.Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma Alemtuzumab in CLL and other lymphoid neoplasms.The diagnosis, staging, and treatment options for mycosis fungoides.Receptor-directed therapy of T-cell leukemias and lymphomas.

P2860

Q26746551-7BAE428F-C380-4963-A193-351D8CABACBF Q27022373-C783C052-36ED-478F-A215-D5E08C8E174D Q27024076-74AA288A-AC80-4886-8C00-BD920AFA1396 Q28075343-911BBC94-7C79-42BF-8FE0-C4880889309E Q30244553-A6EB6FB5-2228-455A-ABD4-B63B06594F85 Q33386506-5DD419F3-9BE6-4A2E-A7E9-EEC05A556AA1 Q33388189-6497021C-ECA1-495E-B2C4-98C82425C4AF Q33434322-A101D547-EC40-4E72-9694-FBF50DC7D83E Q33726963-BB1F006E-1207-48F0-8335-1F878D99C411 Q34156362-01EC8D4C-43A2-46D1-B04D-7B8B836B5810 Q34222228-4FB80365-26BB-4AA5-9E87-9A1D3989392C Q34309399-2FA11AD6-651B-4A12-905B-D76FA5A2CB1C Q34516083-026ADB7C-200C-4175-AB79-2968B03FBEAE Q34532546-44BB281C-6CCB-4E49-AE75-DAA1897D9467 Q34549285-19A60192-9D40-45F6-93F5-8E6DD833137A Q34571555-06FA72BA-34FB-4643-A487-2B176DEDFBC7 Q34574172-9744644B-BF62-46E1-B777-7342E8A6416C Q34700655-3BE954A4-DC3C-4812-B1C9-FE525D8B1D5B Q35022833-73980B04-E3CA-4840-B193-F3489C2B718C Q35583232-A61E0163-C673-40B3-9A52-135D1B27D806 Q35821012-B533531A-14CF-40FD-AF79-6C15149E7507 Q35847654-085F2DF8-E348-45A9-A7F2-AB6416E39C13 Q35852262-B7B83A4F-5B66-4032-9460-C20D6FADC1B8 Q35908498-AFB63618-9BEC-4426-8476-74D6A359A0D3 Q36026719-0902116E-BBD9-44AC-841E-4B57FB2D50A3 Q36150634-8D1AB841-CEB7-40FA-9F0D-12DFC67CE4F8 Q36161365-ACE70B14-8941-4350-9D87-110A3F34AB37 Q36231758-AC810CB7-82B0-4332-8B2E-816958BDD64F Q36243536-C0441A69-4174-43F9-BC40-E35CEAE714B4 Q36349776-F5988D48-9D07-43E8-9EC1-DFB3DA64DAE1 Q36365590-6BFB91A9-43A3-435F-B804-5809B1FF4DC4 Q36367929-FE9408C4-932F-49E0-8539-DBF4487FCC61 Q36383242-262CC763-A1FF-4748-869F-394A335B2961 Q36429723-0D9DF714-694C-4762-86C7-D3633759D27B Q36455996-52838BFF-038F-4E41-850C-D1FD0196DD56 Q36470196-6C52C2AD-D6A3-4071-BF60-4B9D9C34038C Q36519044-C8A3FE46-E6DD-4887-B7AE-012BFE62DF80 Q36659824-7EA81412-3F57-4A28-B22B-BDA90DD56CD2 Q36771218-1678C3D2-109A-40B3-BE6E-97EDD1D7EF94 Q37196716-8741383F-F5EE-4BDB-8033-6A630ED1CB49

P2860

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

http://www.wikidata.org/entity/Q40566975

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Phase 2 study of alemtuzumab ( ...... sis fungoides/Sezary syndrome.

@en

type

label

Phase 2 study of alemtuzumab ( ...... sis fungoides/Sezary syndrome.

@en

prefLabel

Phase 2 study of alemtuzumab ( ...... sis fungoides/Sezary syndrome.

@en

P1433

Q40566975-BC6F82C9-4500-4D82-B187-EA3323AD9B3A

P1476

Q40566975-BD8ABA7C-8D7A-49F6-8C09-0C5D0D5C83E0

P2093

Q40566975-0DC84E64-3DAE-489C-96D4-C74830AE37FD

Q40566975-5BCFA0A7-93BF-48B4-8DA1-08F3B0FC3A46

Q40566975-768F276F-9657-498A-9D8F-78FD3790C18E

Q40566975-8DDFD86A-6875-4D7E-A4F9-254C701997AA

Q40566975-9CD64ADE-DF71-4EEF-97EF-BD52A9929199

Q40566975-C0475047-9E7B-4AC2-A5F5-AB2F05710D64

Q40566975-C505D981-FE0B-465B-A9EA-B2A7F5230306

Q40566975-CC53B946-AB4A-4B17-BD30-8C94B5FA117F

Q40566975-D84984CE-DFB3-42F3-B6B2-58825DA7D592

Q40566975-F26D2B58-392B-4EBD-AAB7-EC14DCFB2F85

P304

Q40566975-676D59FF-64C1-4FEA-83A5-8299D03C0213

P31

Q40566975-4227A321-1330-455F-9D3C-2BAEB272475D

P356

Q40566975-4E0141E9-5AF2-451F-8D3D-7960F2F74338

P407

Q40566975-45766FE0-40DE-4388-AF1C-8F97707F89EB

P433

Q40566975-A2EB6C3F-9D76-4F92-AAA1-BC941E5092BE

P478

Q40566975-C0A977F5-2E14-447C-BB47-9D56FBE5D396

P50

Q40566975-7357B6B3-D393-4DDF-957B-6D88067D51C9

P577

Q40566975-2948F5E7-3E9B-47C8-9AA2-20C97758AB91

P5875

Q40566975-724BD1ED-FEA5-42DB-81A3-6CC81DEE5A12

P698

Q40566975-2717FAF6-71F1-4E6F-8375-251BAC30805F

P921

Q40566975-5D14485D-F474-4EAD-96EB-9843320C7429

P356

BLOOD-2002-09-2802

P1433

P1476

Phase 2 study of alemtuzumab ( ...... sis fungoides/Sezary syndrome.

@en

P2093

Anders Osterborg

http://www.w3.org/2001/XMLSchema#string

Eija Rosenblad

http://www.w3.org/2001/XMLSchema#string

Eva Cavallin-Ståhl

http://www.w3.org/2001/XMLSchema#string

Geir Tjønnfjord

http://www.w3.org/2001/XMLSchema#string

Gunnar Juliusson

http://www.w3.org/2001/XMLSchema#string

Hans Hagberg

http://www.w3.org/2001/XMLSchema#string

Jeanette Lundin

http://www.w3.org/2001/XMLSchema#string

Roland Repp

http://www.w3.org/2001/XMLSchema#string

Susanne Fredén

http://www.w3.org/2001/XMLSchema#string

Tom Wiklund

http://www.w3.org/2001/XMLSchema#string

P304

4267-4272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-09-2802

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Eva Cavallin-Ståhl

P577

2003-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10936598

http://www.w3.org/2001/XMLSchema#string

P698

12543862

http://www.w3.org/2001/XMLSchema#string

P921